Effect of N-acetylcysteine on preventation of postcardiac surgery atrial fibrillation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201008134561N1

Enrollment

240

Registered

2011-05-29

Start date

2010-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation. Atrial fibrillation and flutter

Interventions

Intervention 1: Intervention group take 1200mg tab q12h NAC from 48 before till 72 hour after surgery. Intervention 2: Control group take placebo.

Prevention

Placebo

Intervention group take 1200mg tab q12h NAC from 48 before till 72 hour after surgery

Control group take placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: primary elective coronary artery and/or valve surgery, older than 18 years of age in normal sinus rhythm. Exclusion criteria: prior coronary revascularization or heart valve surgery, emergency surgery, New York Heart Association class III or IV congestive heart failure, history of AF, hyperthyroidism, inflammatory diseases except coronary artery disease, infection, a left atrium size 70 mm, electrolyte imbalance, and ejection fraction 0.25

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Postoperative atrial fibrillation. Timepoint: before and up to 48h after surgery. Method of measurement: ECG holtermonitoring.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Kazemi

Cardiac Research Center of Tabriz UniversityOf Medical Sciences

bkazemia1966 @yahoo.com+98 41 1337 2958

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026